StreetInsider.com News Articles

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.

For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.

United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 21:30:00 -0400

MONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 288,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of six new employees.

The Options have a grant date of July 1, 2026, and an exercise price of $1.32 per share, which

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 21:30:00 -0400

The Options have a grant date of July 1, 2026, and an exercise price of $1.32 per share, which

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 21:30:00 -0400

The Options have a grant date of July 1, 2026, and an exercise price of $1.32 per share, which

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 21:30:00 -0400

The Options have a grant date of July 1, 2026, and an exercise price of $1.32 per share, which

Alpha Cognition names Dr. Robert Wills as board chairman

Tue, 23 Jun 2026 08:30:38 -0400

Alpha Cognition Inc. (Nasdaq: ACOG) has elected Dr. Robert Wills as Chairman of the Board, succeeding Len Mertz, who has retired from the board after serving as chairman since 2021, according to a press release from the biopharmaceutical company.

Dr. Wills has served on Alpha Cognition's board since 2025 and currently chairs the Governance and Nominating Committee while also serving on the Audit Committee. He also serves as Chairman of the Board of Milestone Pharmaceuticals Inc. (Nasdaq: MIST) and as a board member at Parion Sciences Inc.